Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Chemistry Playbook Launched

By Drug Discovery Trends Editor | April 15, 2010

Cambridge Major Laboratories, Inc., Avantium Pharma, Xcelience, LLC, and Beckloff Associates have formed a consortium of expert client-focused companies to launch Chemistry Playbook, a series of proven, modular, expedited CMC solutions designed to accelerate drug development from carbon to commercialization.

Quality can vary across functional business units within larger service providers, but Chemistry Playbook’s consortium model guarantees functional expertise and accountability at every stage. Features and services include Gantt charts and handoffs for individuals or the entire team; and integrated commercial and billing processes to provide natural pull and ease of doing business.

Beckloff Associates (Overland Park, Kan.) offers regulatory oversight; Cambridge Major Laboratories (Germantown, Wisc.) provides API services; Avantium Pharma (Amsterdam, The Netherlands) offers solid state characterization; and Xcelience (Tampa Bay, Fla.) for formulation development expertise.

The consortium launched Chemistry Playbook at a symposium at the headquarters of the Massachusetts Medical Society in Waltham, Mass.

Avantium Pharma’s Vice President Business Development (North America), Andrei Winkler illustrated the advantages of accessing functional expertise across a series of integrated service providers. Beckloff Associates President, Michael Beckloff said, “Innovator companies of all sizes are under pressure to meet critical milestones faster. Execution-based programs can provide significant advantage through time and cost savings.”

This news was featured in Drug Discovery & Development magazine: Vol. 13, No. 3, April 2010, p. 37.

 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE